- Climate change-related risks (extreme weather, policy and legal risks, technical and market risks).
- Potential supply chain disruptions.
Alphamab Oncology
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, Alphamab Oncology disclosed greenhouse gas emissions of 12.8K tonnes of CO2 equivalent. By scope: Scope 1: 4.0K tonnes of CO2 equivalent; Scope 2: 8.8K tonnes of CO2 equivalent. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
12.8K tonnes of CO2 equivalent
2023
Water Usage
180.0K m3
2023
Waste
273.65 tons
2023
Energy Use
35.1K '000kWh
2023
📊 Emissions by Scope (2023)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 4.0K tonnes of CO2 equivalent |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 8.8K tonnes of CO2 equivalent |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
✅ Reported Environmental Achievements
- Reduced greenhouse gas emission intensity by 76.04% compared to 2020.
- Reduced energy consumption intensity by 72.46% compared to 2020.
- Reduced water consumption intensity by 71.42% compared to 2020.
- Reduced total waste emissions by 24.05% compared to 2022.
🌱 ESG Focus Areas
Environmental ManagementSocial ResponsibilityCorporate Governance